Akebia Therapeutics (AKBA) Misses Q3 EPS by 25c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.42), $0.25 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $60 million versus the consensus estimate of $84.9 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Cerebras Q1 EPS miss sends shares down 9% after-hours